| Current use of direct oral anticoagulant | Current use of warfarin |
---|---|---|
Total | 280,407 | 92,339 |
Age as of 1 Mar 2020 | Â | Â |
18– < 40 | 510 (0.2) | 112 (0.1) |
40– < 50 | 2320 (0.8) | 361 (0.4) |
50– < 60 | 12,788 (4.6) | 2245 (2.4) |
60– < 70 | 42,407 (15.1) | 9824 (10.6) |
70– < 80 | 98,848 (35.3) | 34,051 (36.9) |
80+ | 123,534 (44.1) | 45,746 (49.5) |
Median, IQR | 78 (71–84) | 79 (73–85) |
Sex | Â | Â |
Female | 122,778 (43.8) | 36,414 (39.4) |
Body mass index | Â | Â |
 < 18.5 | 5437 (1.9) | 1199 (1.3) |
18.5–24.9 | 72,658 (25.9) | 21,998 (23.8) |
25–29.9 | 94,621 (33.7) | 31,981 (34.6) |
30–34.9 | 57,590 (20.5) | 19,592 (21.2) |
35–39.9 | 24,032 (8.6) | 8114 (8.8) |
40+ | 12,586 (4.5) | 4539 (4.9) |
Missing | 13,483 (4.8) | 4916 (5.3) |
Ethnicity | Â | Â |
White | 201,046 (71.7) | 66,800 (72.3) |
Mixed | 548 (0.2) | 115 (0.1) |
Asian/Asian British | 3911 (1.4) | 766 (0.8) |
Black | 1289 (0.5) | 258 (0.3) |
Other | 1100 (0.4) | 281 (0.3) |
Missing | 72,513 (25.9) | 24,119 (26.1) |
Index of multiple deprivation | Â | Â |
1 (least deprived) | 57,570 (20.5) | 17,703 (19.2) |
2 | 56,881 (20.3) | 18,400 (19.9) |
3 | 55,654 (19.8) | 19,056 (20.6) |
4 | 54,758 (19.5) | 18,615 (20.2) |
5 (most deprived) | 55,544 (19.8) | 18,565 (20.1) |
Smoking status | Â | Â |
Never | 101,492 (36.2) | 33,005 (35.7) |
Former | 161,752 (57.7) | 54,463 (59.0) |
Current | 16,828 (6.0) | 4834 (5.2) |
Missing | 335 (0.1) | 37 (0.0) |
Hazardous alcohol use | 28,375 (10.1) | 7819 (8.5) |
Care home residence | 8133 (2.9) | 1039 (1.1) |
Comorbidities | Â | Â |
Hypertension | 195,078 (69.6) | 66,888 (72.4) |
Heart failure | 71,427 (25.5) | 26,926 (29.2) |
Myocardial infarction | 31,911 (11.4) | 10,414 (11.3) |
Peripheral arterial disease | 14,273 (5.1) | 5091 (5.5) |
Stroke/transient ischaemic attack | 60,271 (21.5) | 18,470 (20.0) |
Venous thromboembolism | 19,927 (7.1) | 8202 (8.9) |
Diabetes | Â | Â |
Controlled (HbA1c < 58 mmols/mol) | 61,178 (21.8) | 23,893 (25.9) |
Uncontrolled (HbA1c ≥ 58 mmols/mol) | 22,672 (8.1) | 7696 (8.3) |
HbA1c not measured | 838 (0.3) | 298 (0.3) |
COPD | 36,189 (12.9) | 11,272 (12.2) |
Other respiratory diseases | 16,444 (5.9) | 4731 (5.1) |
Cancer | 49,488 (17.6) | 16,240 (17.6) |
Immunosuppression | 1688 (0.6) | 528 (0.6) |
Chronic kidney disease | 95,715 (34.1) | 34,633 (37.5) |
Primary care consultations | ||
Median, IQR | 10 (6–17) | 16 (9–27) |
Min, Max | 0, 432 | 0, 307 |
A&E attendance | Â | Â |
Median, IQR | 0 (0–1) | 0 (0–1) |
Min, Max | 0, 69 | 0, 45 |
Flu vaccination | 220,153 (78.5) | 78,558 (85.1) |
Medications | Â | Â |
Oestrogen/oestrogen-like drugs | 1652 (0.6) | 361 (0.4) |
Antiplatelets | 19,030 (6.8) | 4108 (4.4) |